Flomin

Selected form

Solifenacin

Method of action: Anticholinergic, Antispasmodic, Urologicals

Treatment option: Bladder Hyperactivity, Enuresis, Incontinence, Urinary Frequency

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flomin

Quick Facts

Property	Description
Active ingredient	Solifenacin succinate
Form	Film-coated tablets, Oral suspension
Pharmacological class	Anticholinergic (Antimuscarinic)
Common use	Relief from symptoms of bladder overactivity
Origin	Synthetic compound

What Type of Medicine is Flomin?

Flomin is a prescription-only medicinal product classified as an anticholinergic agent, specifically an antimuscarinic, used to modulate muscle activity in the urinary tract. Its sole active ingredient is Solifenacin succinate, a synthetic compound. This classification is standard for the medicinal product.

Flomin is formulated for oral administration and is supplied primarily as film-coated tablets but may also be available as an oral suspension, a feature distinguishing it from some competitors and allowing for administration to a broader patient group. The composition is that of a single active ingredient product, focused entirely on delivering the targeted therapeutic effect of Solifenacin succinate to stabilize bladder function.

Flomin’s Mechanism for Bladder Control

The medicine works by selectively blocking specific communication points, known as M3 muscarinic receptors, found on the bladder muscle to promote relaxation. Flomin functions as a competitive muscarinic receptor antagonist, preventing the body’s natural signals from triggering unwanted or premature muscle contractions.

This targeted action prevents excessive nerve signaling and reduces the abnormal tone and spasms of the detrusor muscle. The goal of this physiological effect is to allow the bladder to gradually increase its functional storage capacity by maintaining muscle relaxation. This mechanism represents the standard action for this drug class.

What is the General Therapeutic Benefit of Solifenacin?

The general therapeutic benefit of Flomin is the stabilization of bladder function, providing relief from the disruptive symptoms associated with bladder overactivity. By achieving focused control over the detrusor muscle spasms, the drug mitigates the involuntary and excessive urge to urinate.

This controlled mechanism assists the patient's body in deferring urination, directly addressing the foundational problem of frequent and compelling sensations of needing to pass urine (urinary urgency). The core purpose is, therefore, to improve the regularity and control of the urinary system's storage phase, which is a typical use scenario for this pharmacological class.

Regulatory References

What side effects are possible with Flomin?

Possible Side Effects and Safety Information

The safety profile of Flomin (Solifenacin succinate) is structured by government regulatory documents based on the drug's anticholinergic properties. Adverse reactions are classified by frequency, with the most commonly reported effects being those related to the gastrointestinal system and the eyes.

Classification	Examples of Documented Side Effects
Common	Dry mouth, Constipation, Blurred vision, Urinary tract infection
Uncommon	Nausea, Vomiting, Dyspepsia (Indigestion), Dizziness, Dry skin, Fatigue
Rare	Severe Urinary Retention, Anaphylactic reactions, Hallucinations, Confusional state

Serious adverse reactions are explicitly noted in regulatory labeling, including severe Angioedema (swelling of the face, lips, tongue, and/or larynx) and systemic Anaphylactic Reactions. The potential for acute and severe Urinary Retention is also documented, particularly in patients with pre-existing conditions.

Safety constraints necessitate specific caution or avoidance in certain groups. The medicine is contraindicated in patients with conditions such as Severe gastric retention, Urinary retention, and Uncontrolled narrow-angle glaucoma. Use is generally not recommended for individuals with Severe Hepatic Impairment due to significantly increased drug exposure. Additionally, regulatory documents note that coadministration with potent CYP3A4 inhibitors increases the risk of dose-dependent adverse reactions, and a risk of heat stroke exists due to the drug's effect on sweating.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents characterize Flomin (Solifenacin succinate) overdose primarily through the presentation of severe anticholinergic effects. These manifestations, which result from exposure to doses significantly higher than recommended levels, primarily affect the Central Nervous System and Cardiovascular System.

Officially documented clinical signs of overexposure include marked somnolence, hallucinations, delirium, and convulsions. Other signs are mydriasis (pupil dilation), tachycardia, and urinary retention.

Overdose is classified by the severity of these anticholinergic signs and the potential for life-threatening complications, such as respiratory failure or severe cardiac issues. Regulatory guidance mandates that individuals seek immediate medical attention for suspected overdose.

Urgent medical help must be sought if severe signs, including convulsions or respiratory failure, are observed. The officially described management principle is to provide symptomatic and supportive treatment. Specific procedures cited in official labeling may include gastric lavage or administration of activated charcoal. Furthermore, hospital monitoring, including ECG monitoring, is required, and the label specifies that Physostigmine may be used to manage severe central anticholinergic effects.

Therapeutic Uses of Flomin

What Flomin Treats: Main Uses and Benefits

Flomin is commonly used to help manage symptoms related to Overactive Bladder (OAB) syndrome, a condition where functional stability becomes affected, leading to symptoms of heightened physiological activity in the bladder. The medication is applied in contexts involving certain distressing symptoms, primarily the sudden, compelling urinary urgency and the resulting urinary frequency. This provides support that helps ease the overall symptom burden associated with the chronic OAB symptom cluster.

The treatment is considered relevant for the management of the symptom clusters that typically occur with OAB, including the listed frequency and urgency, as well as urge urinary incontinence (involuntary leakage associated with urgency) and nocturia (waking up at night to urinate). The therapy contributes to improved comfort during periods of heightened symptoms.

Treatment for Neurological Bladder Dysfunction

The medication is also considered relevant for use in conditions where symptoms of increased neurological or muscular activity lead to bladder instability, specifically Neurogenic Detrusor Overactivity (NDO). Flomin is applied in scenarios where additional management of discomfort is required, assisting pediatric patients (aged ge 2 years) and adults whose bladder dysfunction is linked to an underlying neurological disorder.

Quick Fact: Therapeutic Focus: Overactive Bladder
Main Therapeutic Focus	Easing urinary urgency and frequency.
Additional Focus	Assists with urge urinary incontinence and nocturia.
Context	Applied in chronic conditions marked by heightened symptoms.

Regulatory References

NIH MedlinePlus overview of Solifenacin

Eligibility and Restrictions for Use

Who Can and Cannot Use Flomin? (Solifenacin Succinate)

Official regulatory documentation defines specific populations who may use Flomin and those who must not, based on the drug's activity and patient health status.

Flomin is contraindicated and must not be used by patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug. Use is also prohibited in patients with conditions like severe hepatic impairment (Child-Pugh C) or severe gastrointestinal diseases such as toxic megacolon.

Restrictions and Age Eligibility

Population Group	Eligibility Status	Restriction/Limitation
Adults	Established Use	Approved for Overactive Bladder (OAB) symptoms.
Children/Adolescents	Restricted Use	Use not recommended for OAB in those under 18; Approved for Neurogenic Detrusor Overactivity (NDO) in patients aged ge 2 years.
Renal/Hepatic Impairment	Conditional Use	Dose must not exceed 5 mg daily for severe renal impairment ( CLcr le 30 mL/ min) or moderate hepatic impairment (Child-Pugh B).
Pregnancy/Lactation	Conditional/Not Recommended	Use during pregnancy is conditional; use during breastfeeding is not recommended.

The regulatory profile dictates that the medicine should also not be recommended for patients with clinically significant bladder outflow obstruction or those at high risk of QT prolongation.

What should I know about interactions with other medicines?

Flomin Interactions with other Medicines and Products

Interaction Scope

Item	Documented Interaction Pattern
Medicinal product categories with documented interactions	Potent CYP3A4 inhibitors, other anticholinergic agents, cholinergic receptor agonists, agents that stimulate GI motility, and products that prolong the QT interval.
Mechanistic basis of interactions	Solifenacin is a substrate of the CYP3A4 enzyme. Anticholinergic additivity in effect. Interference with gastrointestinal motility.

Official Interaction Statements and Restrictions

Co-administration with potent CYP3A4 inhibitors (such as Ketoconazole or Ritonavir) significantly increases the plasma concentration (AUC and C max) of Flomin due to reduced metabolic clearance.
The use of Flomin with other medicinal products possessing anticholinergic properties may lead to additive effects, resulting in more pronounced pharmacologic actions.
Flomin can reduce the efficacy of medicines designed to stimulate gastrointestinal motility, such as Metoclopramide or Cisapride.
An interval of approximately one week must be allowed after stopping Flomin before initiating other anticholinergic therapy.

Population-Specific Constraints

The requirement for a maximum daily dose of 5 mg applies when Flomin is co-administered with a potent CYP3A4 inhibitor in patients with severe renal impairment or moderate hepatic impairment. This constraint is an official regulatory requirement due to the increased exposure risk in these populations.
Food administration has been documented to have no significant effect on the pharmacokinetics of Flomin.

Mechanism of Action

How Flomin Works

Flomin exerts its action by specifically targeting and inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These bacterial enzymes are part of the core DNA management system and are necessary for the cell to relieve supercoiling stress, replicate, and repair its genetic material. The drug acts as an inhibitor, binding to these target sites and physically preventing the enzymes from completing their function.

This targeted molecular interference initiates a cascade within the bacterial cell. The inhibition of DNA gyrase and topoisomerase IV leads to the introduction of irreparable breaks and stress in the bacterial DNA. The resulting damage is incompatible with life, which directly causes the death of the bacterial cell (a bactericidal effect). This action selectively eliminates the bacterial population, which is the mechanism for the reduction of the total bacterial load.

Dosage and Administration Information

How Flomin is Used

The general principle for using Flomin (solifenacin succinate) is based on a standardized oral administration protocol. The medicine is supplied as film-coated tablets (5 mg and 10 mg strengths) and an oral suspension, with the administration route being exclusively oral.

The adult dosing regimen for overactive bladder (OAB) typically begins with an initial dose of 5 mg taken once daily. This frequency is maintained throughout treatment. If the initial dose is well-tolerated but symptoms require additional control, the dose may be increased (titrated) to the maximum recommended daily dose of 10 mg.

Administration context is flexible, as the tablets can be taken either with or without food. Regardless of meal timing, the tablets must be swallowed whole to preserve the intended release characteristics and should not be crushed or chewed. The oral suspension is primarily intended for pediatric patients aged two years and older for neurogenic detrusor overactivity, following a weight-based regimen.

The protocol includes specific dose restrictions for certain patient populations. The maximum daily quantity must be limited to 5 mg for individuals with moderate liver impairment (Child-Pugh B), severe kidney impairment, or when the medicine is taken concurrently with a strong CYP3A4 inhibitor. If a dose is missed, the protocol is to skip the missed quantity and resume the schedule at the next regularly appointed time, rather than doubling the dose.

Recent Clinical Evidence

Research Evidence Overview of Studies for Flomin

Evidence for Use in Overactive Bladder (OAB) Syndrome

The research exploring Flomin was primarily gathered through studies conducted during periods of increased symptom activity. These studies were structured as short-term, placebo-controlled Randomized Controlled Trials (RCTs), which research examined in adult populations. These trials were relevant in evidence describing how symptoms are measured, focusing on outcomes reflecting daily functioning, such as the frequency of urination, the number of urgency episodes, and the volume of fluid voided per urination.

In these controlled research scenarios, studies reported measurements observed in the groups, specifically detailing the data collected during the study period related to the frequency of daily urination and urgency. Research describes how measured symptom data changed in the observed populations with OAB. However, long-term effects are not fully established based on the initial controlled trials. While findings describe patterns observed, evidence is limited regarding the durability of these patterns over many years.

Evidence for Use in Neurogenic Detrusor Overactivity (NDO)

Research was also conducted to explore NDO, a condition marked by functional limitations where bladder control is affected by an underlying neurological issue. These trials included adults and a pediatric population aged 2 years and older. The research examined outcomes related to systemic or functional imbalance by using objective urodynamic measures. These included tracking functional measurements, such as Maximum Cystometric Capacity (MCC) and detrusor pressure.

During these studies, data show patterns related to measured changes in MCC and measured changes in detrusor pressure in the observed cohorts. Studies report how measurements of incontinence episodes changed in the study participants. The follow-up durations for the controlled observation phase in these trials were limited. For the pediatric NDO population, in particular, the sample sizes were modest, meaning data for certain groups remain insufficient.

What is Still Uncertain About the Research

Primarily, the controlled research focused on short-term observation periods, and as such, there is limited information for long-term outcomes, meaning long-term effects are not fully established. For specific groups, such as the pediatric NDO population, sample sizes were modest. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes. Overall, the evidence is part of the record describing what is known—and what is still uncertain.

Key Studies & References

Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis (used for comparison context and symptom outcomes)

Frequently Asked Questions (FAQ)

Common questions about Flomin (FAQ)

Q: Can I drink alcohol while taking this medication?

Official product information advises against drinking alcohol while taking Flomin. Alcohol may increase certain side effects of the medication, such as feeling dizzy or sleepy.

Q: What should I do if I am pregnant or plan to become pregnant?

Regulatory documents state that this medication may potentially cause harm to an unborn baby. Women who are pregnant or planning to become pregnant should consult a healthcare provider regarding the potential risks and appropriate management.

Q: Are there any conditions where I should not take this medication?

Yes, Flomin is contraindicated, meaning it should not be taken, if a person has a known hypersensitivity or allergic reaction to the active ingredient or any other component in the drug. The official product information contains the full list of contraindications for reference.

Q: Does this medicine make you sleepy or affect my ability to drive?

Official information indicates that Flomin can cause side effects like dizziness and sleepiness (somnolence). Due to the potential for these effects, regulatory labels indicate that operating complex machinery or driving should be done with caution until the patient knows how the medication affects them.

Q: What is the proper way to store this medication?

According to official product information, the medication should be kept safely in its original container at room temperature, typically ranging from 68 F to 77 F (20 C to 25 C). It should be stored out of the sight and reach of children.

Q: Can this medication cause an allergic reaction?

Yes, the regulatory labels warn that serious allergic reactions have been reported, including angioedema, which is swelling of the face, mouth, and throat. If symptoms such as swelling, difficulty breathing, rash, or hives occur, immediate medical attention is required, and the medication may need to be stopped.

Q: Can I stop taking this medication suddenly?

Official warnings state that Flomin should not be stopped suddenly. To prevent the risk of increased seizure frequency or other withdrawal symptoms, the dosage should be gradually reduced as recommended by a healthcare provider, rather than being stopped abruptly.

Q: What are the most common side effects of this medication?

Studies and official information indicate that the most common side effects reported in clinical trials include dizziness, sleepiness (somnolence), dry mouth, peripheral edema (swelling of the hands or feet), and weight gain.

Q: Is this medication safe for long-term use?

The official nonclinical data section notes that the safety of long-term use in humans is not fully established. While an increased incidence of tumors was observed in mice during certain studies, the significance of this finding for human long-term use is currently unknown.

Q: Is this medication safe for children?

According to the official product information, there is insufficient data to recommend the use of Flomin in children under 18 years of age for the approved adult uses. Information on specific pediatric indications should be sought from a healthcare provider.

Q: Can this medication cause suicidal thoughts?

Regulatory documents include a warning that medicines in this class may increase the risk of suicidal thoughts or behavior. Patients and caregivers are advised to be vigilant for new or worsening depression, unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms are observed, a healthcare provider should be contacted promptly.

How should Flomin be stored and disposed of?

How to Store and Dispose of Flomin?

Flomin (Solifenacin succinate) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Temperature: Store the medicine at Controlled Room Temperature, which is 20 C to 25 C. The product must be protected from excess heat and freezing (especially the oral suspension).

Protection: Keep the medicine in its original container, tightly closed, and store it away from direct light and excess moisture.

Child Safety: Flomin must be stored out of the sight and reach of children.

Stability Limits: If dispensed as an oral suspension, it must be discarded 28 days after first opening. Tablets in an opened bottle must be discarded after 6 months.